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CObjectives: To estimate the cost-effectiveness of dasatinib and nilo-
tinib compared with high-dose imatinib for people with chronic phase
chronic myeloid leukemia, which are resistant to normal-dose ima-
tinib and compared with interferon- for people intolerant to imatinib,
from the perspective of the UK National Health Service. Methods: An
an area under the curve partitioned survival model was developed to
estimate the cost-effectiveness of dasatinib and nilotinib. Clinical ef-
fectiveness evidence was taken mostly from single-arm trials.
Results: Both progression-free survival and overall survival are highly
uncertain. In the base case, patients take nilotinib for much less time
than dasatinib. Nilotinib is expected to dominate high-dose imatinib,
yielding slightly more (0.32) quality-adjusted life years (QALYs) at
slightly less cost (£11,100 [pound sterling]) per person. Dasatinib is pre-
dicted to provide slightly more (0.53) QALYs at substantially greater
cost (£48,900), yielding a very high incremental cost-effectiveness ratio
of £91,500 QALY against high-dose imatinib. Cost-effectiveness, how-
ever, changes radically under the plausible assumption that the drugs O
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doi:10.1016/j.jval.2011.07.006are taken for the same time. For people intolerant to imatinib, nilotinib
is expected to yield an incremental cost-effectiveness ratio of £104,700/
QALY, and dasatinib £82,600/QALY compared with interferon-. Fur-
ther, both drugs represent poor value formoney for a range of plausible
structural assumptions. Conclusions: The model should be viewed as
an exploratory analysis of the cost-effectiveness of dasatinib and nilo-
tinib because it relies on many assumptions. Whilst clinical data re-
mains immature, the cost-effectiveness of dasatinib and nilotinib for
imatinib-resistant people is highly uncertain. Both nilotinib and dasat-
inib are highly unlikely to be cost-effective versus interferon- for peo-
le intolerant to imatinib.
eywords: chronic myeloid leukemia, cost-effectiveness, cost-utility,
asatinib, decision analytic modeling, Glivec, imatinib, nilotinib, Spry-
el, Tasigna.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Chronic myeloid leukemia (CML) is a form of cancer affecting the
blood, which is characterized by excessive proliferation of white
blood cells in bone marrow and circulating blood. The molecular
hallmark is the presence of an acquired BCR-ABL fusion gene in
myeloid progenitors. In the United Kingdom, an estimated 530
new cases of CML are diagnosed each year [1].
Traditionally, CML has been regarded as a progressive disease
that evolves through three phases. The initial chronic phase, dur-
ing which the disease is stable and slow to progress, is followed
after a variable interval by progression through an accelerated
phase to a rapidly fatal blast crisis. Most people (approximately
90%) are diagnosed during the chronic phase [2].
Imatinib was the first tyrosine kinase inhibitor in CML, and has
been widely used. Trials of imatinib are ongoing, but current evi-
dence suggests that people whose disease responds to treatment
with imatinib may remain symptom-free for at least 10 years [3].
Current National Health Service (NHS) treatment options for CML
include imatinib and allogeneic hematopoietic stem cell trans-
plantation [4]. Stem cell transplantation is not a treatment option
* Address correspondence to:MartinHoyle, Senior Research Fellow
Peninsular College of Medicine and Dentistry, University of Exeter
E-mail: martin.hoyle@pms.ac.uk.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.formany people. Resistance to imatinib is awell documented clin-
ical problem and may be primary (initial refractoriness to ima-
tinib) or acquired (develops during treatment) [5,6]. Imatinib resis-
tance has been variously defined. For instance, in a recent clinical
trial of dasatinib, imatinib resistancewas defined as a lack of com-
plete hematological response after 3 months of imatinib treat-
ment, a lack of any cytogenetic response after 6 months of treat-
ment, a lack of a major cytogenetic response (Ph-positive cells 
5%) after 12 months of treatment, an increasing white blood cell
ount on at least two consecutive occasions or a relapse after a
omplete hematological response or major cytogenetic response
7]. Imatinib intolerance is frequently defined as at least grade 3
on-hematological toxicity or grade 4 hematological toxicity per-
isting for more than 7 days, related to imatinib at any dose [7].
Available treatment options for imatinib-resistant or -intoler-
nt disease include dasatinib, nilotinib, high-dose imatinib (800
g per day), interferon-, and hydroxycarbamide. Dasatinib
(Sprycel, Bristol-Myers Squibb Company, Princeton, NJ) and nilo-
tinib (Tasigna®, Novartis Pharmaceuticals Corporation, East Han-
ver, NJ) are oral second generation tyrosine kinase inhibitorswith
ctivity against a range of tyrosine kinases. Dasatinib and nilotinib
re licensed for the treatment of adults with chronic and acceler-
TAModelling, Peninsula TechnologyAssessment Group (PenTAG),
sey Building, Salmon Pool Lane, Exeter, EX2 4SG, UK.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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1058 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 5 7 – 1 0 6 7ated phase CML with resistance or intolerance to prior therapy,
including imatinib, andwho received accelerated approval for this
indication by the US Food and Drug Administration (FDA) and the
EuropeanMedicinesAgency (EMEA) [8,9]. Dasatinib is also licensed
for the treatment of blast phase CML.
The cost-effectiveness of dasatinib or nilotinib for treatment of
CML has not previously been published in full by a financially
independent research team. Bristol-Myers Squibb (BMS), theman-
ufacturer of dasatinib, andNovartis, themanufacturer of nilotinib,
recentlymade submissions to the National Institute of Health and
Clinical Excellence (NICE), which included cost-effectiveness anal-
yses for dasatinib and nilotinib [3]. In addition, dasatinib has re-
ently been assessed as a good value for money compared with
igh-dose imatinib for patients resistant to standard dose ima-
inib in Sweden, according to a study with financial support from
MS [10]. The decision analytic model, and subsequent cost-effec-
iveness analysis, presented here formed part of the independent
ssessment report submitted to NICE (by the authors) and were
sed to inform the NICE Health Technology Appraisal process [3].
The analysis is confined to people starting treatment in chronic
hase CML. We have not modeled people starting treatment in
ccelerated phase or blast phase CML because we found no appro-
riate clinical effectiveness data for a comparative treatment [3].
Based on advice from our expert advisory group, we chose high-
dose imatinib as the most appropriate comparator for people re-
sistant to normal-dose imatinib and interferon- for people intol-
erant to imatinib [3].
Methods
Model structure
An area under the curve partitioned survival Markov-type model
(see for example [11]) was developed tomodel disease progression
in CML and treatment effectiveness of all drugs. In this type of
model, the number of patients in each health state at any time is
determined directly from the underlying survival curves. This was
preferred to a conventional Markov approach for two reasons.
First, it bypassed the need to estimate transition probabilities and
second, it avoided the need for additional assumptions, such as
whether death was permitted from all health states. The model
was written in Microsoft Excel (Microsoft Corporation, Redmond,
WA). The structure of the model was informed by a review of the
available literature, clinical guidelines for treatment of CML, and
expert opinion on the clinical progression of the disease [3].
Five health states were used to represent progression of CML:
chronic phase on second line treatment, chronic phase on third
line treatment, accelerated phase, blast crisis, and death. At the
end of each cycle people either remain in their current health state
ormove to amore severe state. The timebetweensecond-line treat-
ent discontinuation and death is treated as a single meta-state,
omprising chronic phase on third-line treatment, accelerated
hase, and blast crisis. Thismeans that, in terms of its internal logic,
hemodel has only three states: chronic phase on second-line treat-
ent, death, andall time inbetween.Onceoccupancyof these states
as been calculated, the post–second-line discontinuation (pre-
eathperiod) is split into threeparts: first, aperiodestimating time in
last crisis is deducted, then time in accelerated phase is deducted,
nd timeon third-line treatment in chronic phase is estimatedas the
emainder. For simplicity, for the purposes of discounting, it is as-
umed that all people enter accelerated phase and blast crisis just
efore themean overall survival time for each treatment. It is neces-
ary tomodel time on third-line treatment in chronic phase because
he definitions of progression included criteria other than develop-
ent of accelerated phase CML [3], and clinical experience indicateshat people may spend several years in the chronic phase after de-veloping signs of “progression,”which results in treatment cessation
(see Figure 2 in Jabbour et al. [12]).
Two separate models were implemented: one simulating a co-
hort of people resistant to normal-dose imatinib, and one simu-
lating people who are intolerant to imatinib. All people enter the
model in chronic phase CML on second line treatment, having failed
on treatment with normal-dose imatinib. In commonwith the clini-
cal trials of dasatinib and nilotinib, the male to female ratio was
assumed 1:1 and people were assumed to start second-line treat-
ment aged 56. People were modeled until age 100, giving a 44-year
time horizon (effectively lifetime), and a 2-monthmodel cycle (short
enough to capture all clinical events), with half-cycle corrections.
Future costs and benefits were discounted at 3.5% per year [13].
Follow-up of trials of dasatinib and nilotinib are short, and pa-
tients typically survive for many years with chronic phase CML.
Therefore overall survival was very immature at data cut-off (e.g.,
89% alive after 2 years on dasatinib for imatinib-resistant patients
and 88% alive after 1.6 years on nilotinib imatinib-resistant pa-
tients). Consequently, we did not extrapolate the empirical overall
survival. Instead, overall survival was estimated according to the
proportion of people for each treatment that achieved a major
cytogenetic response (MCyR), a known surrogate for overall sur-
vival [3,14,15]. In summary,Weibull curveswere specified for CML-
cause mortality for responders (achieving a MCyR) and non-re-
sponders (not achieving a MCyR). In common with Anstrom et al.
[15], we assumed a constant hazard ratio between these curves. A
review of trials of normal-dose imatinib yielded a pooled estimate
of the hazard ratio as 0.370 (95% confidence interval [CI], 0.156–
0.876) [3]. We applied this hazard ratio to all treatments. Next,
these curves were adjusted for non-CML mortality [3,16]. Finally,
the Weibull parameters were estimated by calibrating the mod-
eled overall survival for high-dose imatinib against the empirical
overall survival for high-dose imatinib from Jabbour et al. [12]. This
trial was selected because it provides the longest available esti-
mate of overall survival in a population taking a tyrosine kinase
inhibitor in a population who have failed on normal-dose ima-
tinib. The overall survival curve for any treatment was then calcu-
lated as the sum of the overall survival curve for responders and
the curve for non-responders, weighted by the proportion of peo-
ple achieving a MCyR for that treatment.
Duration of treatment is a key input in the estimation of the
costs of the drugs. In the trials, all drugs were taken until disease
progression, occurrence of serious adverse events or death. There-
fore, the estimated treatment duration survival curves were based
on the extrapolated progression-free survival (PFS) from the rele-
vant trials. The projected PFS curve for those people who stopped
treatment due to adverse events or other causes was deducted,
weighted by the proportion of people who stopped treatment for
each drug. Ideally, the PFS curve for those people who stopped
treatment due to serious adverse events or other causes would be
assumed to follow the PFS survival curve for no active treatment.
Given that such data is unavailable, however, the curve was as-
sumed to follow the modeled overall PFS for interferon-, where
we assumed that interferon- delays progression only slightly
compared with no drug treatment. Following consultation with
our expert advisors, we assumed that patients would stop drug
treatment mostly due to serious adverse events, at 3 months.
PFS was estimated allowing for general mortality and sepa-
rately for progression excluding general mortality. PFS for high-
dose imatinib was estimated as follows. First, PFS excluding gen-
eral mortality was assumed to follow a Weibull curve. Similar to
the estimation of overall survival above, overall PFS (including
generalmortality) was calculated fromprogression excluding gen-
eral mortality plus the rate of general mortality. Next, this overall
PFS was compared with the empirical PFS from Jabbour et al. [12].
Then, the parameters of theWeibull curve for PFS, which excludes
general mortality, were estimated by regressing the expected
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1059V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 5 7 – 1 0 6 7overall PFS against the empirical PFS. PFS for all other drugs was
also estimated allowing for general mortality and separately for
progression excluding general mortality. Given that follow-up for
empirical PFS for these drugs is very short (up to 2 years, see Clin-
ical Effectiveness section), at which time a large proportion of pa-
tients are still progression free, we have insufficient data to mea-
sure the shape of the distribution. Therefore PFS excluding general
mortality was modeled by an exponential curve separately for
each drug and patient population.
We found no data on the time people spend in accelerated phase
and blast crisis following chronic phase treatment with dasatinib,
nilotinib, and high-dose imatinib. This is not surprising because
these drugs are relatively new, and people typically takemany years
from diagnosis to reach these health states. In common with other
models of the cost effectiveness of treatment for CML [17–20], time
spent in accelerated phase and blast crisis was assumed indepen-
dent of treatment arm. This assumption seems reasonable, given
that second line treatment typically stops several yearsbeforepeople
enter these health states. In particular, mean times in accelerated
and blast phases of 9.6 and 13.1 months respectively were assumed,
taken from a previous cost-effectiveness analysis in CML in which
these values were estimated from published survival curves [20].
In the base case, the costs of treating adverse events, and the
disutility associated with their incidence are not explicitly in-
cluded, except via a lower utility while on treatment with interfer-
on- compared with the other drugs. This simplifying assumption
as adopted for the following three reasons: (1) the incidence of
erious adverse events on high-dose imatinib, dasatinib, and nilo-
inib is relatively low [3]; (2) clinical opinion suggests that the cost
f treating people with these adverse events is likely to be low; (3)
iven the substantialmodel structural and parameter uncertainty,
odeling the costs and disutilities associated with adverse events
ould introduce spurious accuracy.
Ideally, the parameter inputs would have been drawn from
andomized trials directly comparing the various treatments sim-
lated in the model. In the absence of such evidence, we were
egrettably forced to rely on estimates taken fromaheterogeneous
ollection of observational studies with single arms (or single rel-
vant arms). Some of the guiding principles for the derivation of
odel inputs were as follows: derive as many parameters as pos-
ible from the same trial for a given treatment; wherever possible,
eparate parameter inputs for imatinib-resistant and -intolerant
Fig. 1 – Predicted overall survival for imatinib-resistant peop
nilotinib, and high-dose imatinib are represented by an asteopulations should be obtained; where possible data should rep- nesent a large sample size and long follow-up. Patient baseline
haracteristics for the relevant trials are given in the online Ap-
endix in Supplemental Materials at: 10.1016/j.jval.2011.07.006.
Clinical effectiveness
Major cytogenetic response rates. Our systematic review of clinical
effectiveness identified several trials in which MCyR is reported
for each treatment [3]. It is important to recognize that MCyR rates
reflect best-ever status on treatment (as opposed to current status
at the time of analysis). This means that, as follow-up extends,
response rates can only increase. Hence, it was imperative to use
model parameters with MCyR rates that represent the likelihood
of response at a single, uniform juncture for each comparator. On
scrutiny of the evidence, we selected 12 months as the follow-up
time that could most accurately be derived or approximated for
each of the comparators for imatinib-resistant CML; and 6-month
follow-up for imatinib-intolerant CML (as MCyRs were available
only at this follow-up time in the trials; Table 1).
Treatment duration. Here, we explain our choice of PFS and our
choice of rates of premature discontinuation from treatment, both of
which are used to estimate treatment duration, as explained above.
For dasatinib and nilotinib, PFS split according to imatinib-resistant
and -intolerant people from the relevant clinical trials are not pub-
lished [21,22]. Instead, for dasatinib, the following PFS datawasused,
which was provided in the submission of Bristol-Myers Squibb to
NICE [23]: 0.77 for imatinib-resistant people and 0.87 for imatinib-
ntolerant people at 2-year follow-up. For nilotinib, the following PFS
ata was used, which was provided in the submission of Novartis to
ICE [24]: 0.864, 0.769, and 0.632 for imatinib-resistant people and
.951, 0.906, and 0.845 for imatinib-intolerant people at 6, 12, and 18
onths, respectively. For high-dose imatinib, the full Kaplan-Meier
FS curve over 7-year follow-up from Jabbour et al. [12] was used, the
ame trial from which the MCyR was sourced. For interferon-, the
ull Kaplan-Meier PFS curve over 2-year follow-up from the Interna-
ional Randomized Study of Interferon and STI571 (IRIS) trial [6] was
sed, our source for other parameters for this treatment.
The treatment withdrawal rates at 3 months were taken from
he same trials as those for PFS, except for high-dose imatinib
hich was calculated as a pooled estimate over several trials of
igh-dose imatinib [3], given that the withdrawal rate is not re-
orted in Jabbour et al. [12]. The rates were 10.2% dasatinib, 23.2%
treatment and by response. The curves for dasatinib,
. MCyR, major cytogenetic response.le by
riskilotinib, 14.8% high-dose imatinib, 55.3% interferon-.
1060 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 5 7 – 1 0 6 7Health state utilities
A review of the literature identified six sources of utility values for
CML [3]. From these, the following utilities were chosen for people
in chronic phase: for dasatinib, nilotinib, and high-dose imatinib,
0.85 (standard error of the mean [SE], 0.004), for the interferon-
arm; on second-line interferon- treatment, 0.71 (SE, 0.008), for the
interferon- arm; on third-line treatment, 0.85 (SE, 0.004). The util-
ity for all people, regardless of treatment arm in accelerated phase,
was 0.73 (SE, 0.06) and in blast crisis 0.52 (SE, 0.08). These datawere
collected during the IRIS trial, as reported elsewhere [19,20] and
used in a previous assessment of imatinib for CML [25]. The utili-
ties are drawn from a large sample of people, using the EuroQol
five-dimensional questionnaire (EQ-5D), which is preferred in the
NICE reference case [13]. Given that utility values for people taking
dasatinib and nilotinib in chronic phase are not cited in the liter-
ature, we set these values equal to the value for high-dose ima-
tinib in chronic phase based on clinical opinion and the similarity
Fig. 2 – Base case cost-effectiveness acceptability curves for
are given in pounds sterling (£). QALY, quality-adjusted lifeof the incidence of adverse events by treatment.Resource use and costs
Assumptions for resource use were based on expert opinion and
are given in Tables 2 and 3. The perspective for costs is that of the
UK NHS and personal social services.
Based on a sample of UK clinicians, Bristol-Myers Squibb as-
sumed that third-line treatment would cost £2079 (pound sterling)
per 2 months, and would consist of tyrosine kinase inhibitors,
hydroxycarbamide, and stem cell transplantation. We have also
made this assumption (Table 3).
For consistency between the costs of second line drugs and
clinical outcomes, it is necessary to model the amounts of the
second line drugs actually taken while on treatment in the rele-
vant clinical trials. The dose intensity of a drug is defined as the
amount of drug administered in a clinical trial as a proportion of the
amount that would have been administered if there had been no
dose reductions or dose interruptions. The dose intensity estimates
are taken from the same trials from which we sourced the MCyR
atinib-resistant and (B) imatinib-intolerant people. Costs
s; WTP, willingness-to-pay threshold.(A) im
year(Table 1). Ideally,mean dose intensities would be used in our model,
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1061V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 5 7 – 1 0 6 7but these are not reported for all drugs. Instead,median dose intensi-
ies are used for all drugs except high-dose imatinib. Themean dose
as used for high-dose imatinib, calculated from Figure 5 in Jabbour
t al. [12]. In summary, the following dose intensities were chosen:
asatinib 100% (SE, 2.0%), nilotinib 100% (SE, 1.3%), high-dose ima-
inib 92% (SE, 1.3%), and interferon- 56% (SE, 0.9%), where the stan-
ard errors were calculated from the sample sizes and reported
anges of dose intensities across all people in the trials.
Dasatinib, nilotinib, andhigh-dose imatinib are all taken orally,
nd therefore incur no administration costs. Interferon-dose and
dministration schedules are taken from the IRIS trial, with the
ssumption (based on clinical opinion) that interferon- will be
aken at home. We assume that 75% of people administer inter-
eron- themselves, or with the help of a care giver, and in 25% of
ases, administration is carried out by district nurses, as previ-
usly described [11]. The cost of a single district nurse visit during
006 to 2007 is quoted as £24 in pound sterling (Schema 9.1, Com-
unity nurse) [26]. Inflating this value to 2009 to 2010 prices [26],
stimates £27 (SE, £3) per visit. This implies an average cost per
-month model cycle of £409. We do not adjust the cost of admin-
Table 1 – Major cytogenetic rates used in the model.
Parameter Mean
MCyR (s.e.)
Sour
Dasatinib (imatinib-resistant) 58.1% (4.4%) Unpublished data
[21] provided by
the NICE consult
Nilotinib (imatinib-resistant) 52.4% (3.6%) Approximated by l
interpolation be
published 6-mon
194  48.5%; Kan
[22]) and 19-mon
228  56.1%; dat
Novartis as part
consultation pro
High-dose imatinib 44.0% (5.4%) 35 reported MCyRs
cases known to
study baseline/8
Jabbour et al. [16
Dasatinib (imatinib-intolerant) 74.4% (6.7%) Shah et al. [21]
Nilotinib (imatinib-intolerant) 46.5% (5.4%) Kantarjian et al. [2
Interferon- 22.1% (1.8%) O’Brien et al. [6]
BMS, Bristol-Myers Squibb;MCyR,major cytogenetic response; NICE, Natio
Table 2 – Second line drug costs.
Drug Brand name Dose and freq
Dasatinib Sprycel 100 mg once per day
Nilotinib Tasigna 400 mg twice per day
High-dose imatinib Glivec 400 mg twice per day
Interferon- Roferon-A Target dose: 5 million u
meter body surface a
8.65 MU per person p
body area)†
Cytarabine (used with
interferon-)
20mg per m2 body per d
per month†
Costs are given in pounds sterling (£).
* All price data taken from British National Formulary No. 58 [29].
† Dosing regimen taken from International Randomized Study of Interferstration according to the dose intensity of interferon- because
doses tend to be reduced, rather than omitted completely [11].
Sensitivity analyses
One-way sensitivity analyses and probabilistic sensitivity analyses
were performed by varying effectiveness, utility, and cost parame-
ters. One thousand simulations of the model were run in the proba-
bilistic sensitivity analysis. For the probabilistic sensitivity analysis,
utilities followed beta distributions with SE given above, non-drug
costs followed gamma distributions with SE given in Table 3, dose
intensities bynormal distributionswith standard errors given above.
Uncertainty in PFS for all treatments was modeled by consid-
ering the uncertainty in PFS at a certain single time point. Thiswas
estimated fromPeto’s formula [27]. For all treatments except high-
dose imatinib, uncertainty in PFS was modeled by allowing the
parameter of the exponential distribution to vary in such a way
that the PFS probability at the single time point varied as a beta
distribution. For high-dose imatinib, the same method was ad-
Follow-up
(months)
Justification
Shah et al.
as part of
process.
12 Only available estimate at currently
recommended dose of dasatinib
te (94/
n et al.
te (128/
vided by
NICE
.
12 Only available estimate
dditional
MCyR at
4.0%;
61 Estimates of overall survival, PFS, and
MCyR rate all originate from the
same study.
6 Only available estimate at currently
recommended dose of dasatinib
6 Only available estimate
18 Recent, large trial. Estimates of overall
survival, PFS and MCyR rate all
originate from the same study
stitute of Health and Clinical Excellence; PFS, progression-free survival.
y Price* Cost per
2-month cycle
50 mg, 56-tab pack  £2337.97 £5,080
200 mg, 112-cap pack  £2432.85 £5,286
400 mg, 30-tab pack  £1604.08 £6,505
er square
er day 
y (1.73 m2
0.5-mL (4.5 million-unit)
prefilled syringe  £22.60
£2,643
r 10 days 20 mg/mL, 5-mL vial  £4.00 £28ce
from
BMS
ation
inear
tween
th ra
tarjia
th ra
a pro
of the
cess)
 2 a
be in
4  4
]
2]uenc
nits p
rea p
er da
ay foon and STI571 (IRIS) trial [6].
6]. St
1062 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 5 7 – 1 0 6 7opted, but fixing the parameter gamma of theWeibull distribution
and varying the parameter lambda.
Uncertainty in overall survival for all treatments was mod-
eled in the following ways. First, the cytogenetic response rates
for all treatments were varied according to a normal distribu-
tion, with standard errors given in Table 1. Second, the hazard
ratio between responders and non-responders was varied as a
log-normal distribution. Third, uncertainty in the empirical
overall survival data for high-dose imatinib was modeled by
considering the uncertainty in overall survival at a certain sin-
gle time point, again estimated from Peto’s formula [27]. In this
case, the parameter gamma of the Weibull distribution was
fixed, and the parameter lambda was allowed to vary in such a
way that the overall survival probability at the single time point
Table 3 – Medical management and third-line treatment co
Item Population Frequ
Consultant outpatient visits CP treated 4 visits/ye
CP not treated 4 visits/ye
AP 1 visit/mo
BC 2 visits/m
Bone marrow tests CP treated 2 tests/yea
CP not treated none
AP none
BC none
X-rays CP treated none
CP not treated none
AP none
BC 3/month
CT scans CP treated none
CP not treated none
AP none
BC 0.5/month
Blood transfusions CP treated none
CP not treated none
AP none
BC 1/month
Third line treatment CP treated none
CP not treated continuou
AP None
BC none
Inpatient terminal care CP treated None
CP not treated none
AP none
BC 1 stay/mo
stay 3 d
CT, computed tomography; SE, standard error of the mean; CP, chron
Costs are given in pounds sterling (£).
* £108 per visit (n  1) [30], consultant led follow-up attendance, o
without treatment) total attendances. £121 inflated to 2009 to 2010
† £547 per test (no range given) [31] admitted patient care mandatory
at 10% of mean.
‡ £26 (interquartile range £22–£27, n  4) [30], radiology services – ou
calculated from interquartile range and sample size n.
§ £92 (interquartile range £66–£114, n 143) [30], NHS trusts and PCTs
to 2009 to 2010 [26]. Standard error calculated from interquartile ra
 £436 (n  1) [30], NHS trusts and PCTs combined. Consultant le
attendances. Specialty code 821. £490 inflated to 2009 to 2010 [26]. S
¶ From a survey of UK clinicians by Bristol-Myers Squibb [3]. Include
transplantation. Standard error set at 10% of mean.
# £106 (interquartile range £71–£107, n  18) [30]. NHS trusts and PCTs
without treatment). Total attendances. £119 inflated to 2009 to 2010 [2varied as a beta distribution.Results
Imatinib-resistant people
All treatments are expected to yield similar survival gains, with
median overall survival ranging from 9.4 years for high-dose ima-
tinib to 10.8 years for dasatinib (Table 4, Fig. 1). This order of overall
survival reflects the relative proportion of people with a MCyR for
each treatment. Conversely, in the base-case analysis, the time
spent on treatment varies greatly. People are predicted to take
dasatinib for an average of 6.5 years, whereas people are predicted
to take nilotinib or high-dose imatinib for less than half this time.
Consequently, the expected per patient second-line drug cost is
Mean cost (SE) Cost per 2-month
model cycle
£121 (£12) per visit* £81
£81
£243
£486
£615 (£62) per test† £205
none
none
none
£29 (£2) per visit‡ none
none
none
£175
£103 (£3) per scan§ none
none
none
£103
£490 (£49)/transfusion None
None
None
£981
£2,079 (£208) per 2 months¶ None
£2,079
None
None
£119 (£7) per day# None
none
none
ach £715
ase; AP, accelerated phase; BC, blast crisis.
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1063V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 5 7 – 1 0 6 7dose imatinib. The difference in time in chronic phase on second-
line treatment is counterbalanced by time in chronic phase on
third line treatment, which is predicted to last 5 years in the da-
satinib arm, comparedwith about 8 years for those taking nilotinib
or high-dose imatinib. As stipulated in the model structure, the
times in accelerated and blast phases are equal for all treatments.
In the base-case analysis, nilotinib dominates high-dose ima-
tinib; nilotinib is expected to yield 0.32 more quality-adjusted life
years (QALYs) at £11,100 (pound sterling) less per patient (Table 4).
Dasatinib is predicted to provide 0.53moreQALYs thanhigh-dose ima-
tinib at substantially greater cost (£48,900), yielding a very high incre-
mental cost-effectiveness ratio (ICER) of £91,500QALY.Dasatinib is pre-
dictedtoprovide0.22moreQALYsthannilotinibatsubstantiallygreater
cost (£60,000), yielding a very high ICER of £277,700 QALY.
The modeled overall survival for high-dose imatinib was fitted
to empirical trial data, so a very close fit between actual and pre-
dicted overall survival for high-dose imatinib was obtained. The
predicted overall survival for dasatinib and nilotinib were mod-
eled completely independently of the empirical overall survival for
these treatments (because the empirical data is very immature).
Despite this, the overall survival curves from our model predict
the empirical data reasonably well for the short period of the trial
follow-up. At 2 years, the modeled overall survival for dasatinib
was 0.86 compared with the empirical value of 0.89, and at 1.58
years, the modeled overall survival for nilotinib was 0.88 com-
pared with the empirical value of 0.88.
Full one-way deterministic sensitivity analyses are reported in
Rogers et al. [3] and in the online Appendix in Supplemental Ma-
terials at: 10.1016/j.jval.2011.07.006. Some key results for nilotinib
versus high-dose imatinib are as follows. Nilotinib dominates
high-dose imatinib in most sensitivity analyses. Furthermore, ni-
lotinib provides very good value for money compared with high-
dose imatinib in all analyses except when PFS for nilotinib is set
equal to that for dasatinib (and hence the mean treatment dura-
tions are approximately equal), in which case the ICER is £128,000
QALY. This is an important sensitivity analysis because the evi-
dence provided from the drug manufacturers indicates that the
mean treatment duration for dasatinib is much longer than for
nilotinib (see theMethods section), and it appears counterintuitive
Table 4 – Base case results for imatinib-resistant people.
Dasatinib Nilotinib
Life years, mean, undiscounted (95% CI)
Chronic phase 2nd-line drugs 6.5 2.44
(4.95–8.89) (1.66–3.10)
Chronic phase 3rd-line treatment 5 8.65
(1.24–8.89) (3.74–12.75)
Accelerated phase* 0.8 0.8
Blast crisis* 1.09 1.09
Total, mean 13.4 12.98
(7.81–16.95) (7.90–16.90)
Total, median 10.76 10.21
(5.25–15.92) (5.33–15.86)
Total QALYs, mean, discounted 7.846 7.63
Costs, mean, discounted
2nd-line drug £161,432 £70,143
Other £59,893 £91,186
Total £221,325 £161,330
Cost/life year
Cost/QALY
Costs are given in pounds sterling (£).
95% CI, 95% confidence interval; QALY, quality-adjusted life years.
* Uncertainty not simulated.that PFS for the two drugs is very different, whereas overall sur- pvival is very similar (as we assume in our base case). Furthermore,
it appears that clinical opinion in the NICE assessment for these
drugs was that dasatinib and nilotinib would be taken for approx-
imately the same time (NICE Appraisal Consultation, http://
guidance.nice.org.uk/TA/WaveR/99/Consultation/DraftGuidance).
In our base-case analysis, dasatinib is taken for far longer than
nilotinib. Given that there is considerable structural uncertainty in
the assumed relationship between response rate and overall sur-
vival, overall survival was modeled in a completely different way in
one sensitivity analysis. Setting the time inpost-progression survival
in the nilotinib arm equal to the value for high-dose imatinib yields
and ICER of £114,000 QALY, where nilotinib costs less and provides
less benefit that high-dose imatinib. Setting the MCyR for high-dose
imatinib at the upper 95% CI of 54.6% yields and ICER of £202,000
QALY,where nilotinib again costs less and provides less benefit than
high-dose imatinib. Setting the PFS for high-dose imatinib equal to
the lower 95% CI limit yields an ICER of £11,000 QALY.
The cost-effectiveness of nilotinib is far less sensitive to rea-
sonable changes in many other parameters (e.g., the dose intensi-
ties of the drugs), the proportion of people who discontinue treat-
ment prematurely, the overall survival hazard ratio between
responders and non-responders, uncertainty in the empirical
overall survival for high-dose imatinib, medical management
costs, costs of treating adverse events (based on assumptions from
the Novartis model [24]), and utilities (see [3] and online Appendix
in Supplemental Materials at: 10.1016/j.jval.2011.07.006).
The ICER for dasatinib versus high-dose imatinib remains
above £30,000 QALY in all but one sensitivity analysis. In particu-
lar, when PFS for dasatinib is set equal to that for nilotinib or
high-dose imatinib, dasatinib then dominates high-dose imatinib.
We repeat that the sensitivity analysis whereby PFS for dasatinib
is set equal to that for nilotinib (and therefore mean treatment
durations are very similar) is very important, given the clinical
opinion in the NICE assessment for these drugs.
Clinical data for dasatinib was taken from Shah et al [21] be-
ause people in this trial took dasatinib at the recommended dose
f 100mg/d. However, when all the dasatinib clinical effectiveness
ata is taken from either of the two other trials of dasatinib [7,28],
n which people took dasatinib at 140 mg/d, then dasatinib ap-
gh-dose
atinib
Dasatinib vs. high-dose
imatinib
Nilotinib vs. high-dose
imatinib
2.68 3.82 –0.24
02–3.90) (1.29–6.55) (1.80 to 0.56)
7.79 2.79 0.86
40–11.55) (5.23 to 0.02) (0.39 to 3.06)
0.8 0 0
1.09 0 0
12.37 1.04 0.62
83–15.99) (0.08–2.55) (0.04 to 1.71)
9.45 1.31 0.76
14–14.44) (0.08–3.69) (0.04 to 2.37)
7.311 0.535 0.318
£88,883 £72,548 £18,740
£83,532 £23,639 £7,655
172,415 £48,910 £11,086
£47,153 Nilotinib dominates
£91,499 Nilotinib dominatesHi
im
(2.
(3.
(7.
(5.
£ears even less cost effective. Next, although the ICER varies con-
1064 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 5 7 – 1 0 6 7siderably when the MCyR rates are varied within their 95% CI, it
remains high. Indeed, even assuming every patient achieves a re-
sponse on dasatinib, the ICER is £34,500 QALY. Furthermore, the
ICER remains high, at £43,200 QALY when we recalculate overall
survival by setting the time in post-progression survival in the
dasatinib arm equal to the value for high-dose imatinib.
Asmentioned above, the ICER is particularly high because peo-
ple are predicted to take dasatinib for a long time. Even assuming
the lower 95% CI for dasatinib PFS, the ICER remains high at
£46,700 QALY. Cost-effectiveness is far less sensitive to changes in
many other parameters, including dose intensities of the drugs,
overall survival hazard ratio between responders and non-re-
sponders, uncertainty in the empirical overall survival for high-
dose imatinib, medical management costs, costs of treating ad-
verse events (based on assumptions from the Bristol-Myers Squibb
model [23]), and utilities (see [3] and the online Appendix in Sup-
plemental Materials at: 10.1016/j.jval.2011.07.006).
We now turn to the probabilistic sensitivity analysis. In the
Fig. 3 – Cost-effectiveness acceptability curves for imatinib-r
nilotinib is set equal to PFS for dasatinib and (B) PFS for das
pounds sterling (£). QALY, quality-adjusted life years; WTP,base-case analysis, dasatinib generated more QALYs than high-dose imatinib in 95% of the simulations, whereas nilotinib gener-
ated more QALYs in 90%. Dasatinib costs more than high-dose
imatinib per patient in virtually all simulations and nilotinib costs
more than high-dose imatinib in 9% of simulations. At a willing-
ness-to-pay threshold of £30,000 QALY, nilotinib provides the best
value for money in virtually all simulations (Fig. 2A).
Next, in the sensitivity analysis whereby we set PFS for nilo-
tinib equal to that for dasatinib, high-dose imatinib is expected to
provide best value formoney for willingness-to-pay thresholds up
to £100,000 QALY (Fig. 3A). In the sensitivity analysis whereby we
set PFS for dasatinib equal to that for nilotinib, nilotinib is ex-
pected to provide best value for money for willingness-to-pay
thresholds up to £57,000 QALY, thereafter, dasatinib provides best
value for money (Fig. 3B).
Imatinib-intolerant people
Large differences in overall survival are predicted, with interfer-
tant people when (A) progression-free survival (PFS) for
b is set equal to PFS for nilotinib. Costs are given in
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1065V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 5 7 – 1 0 6 7(Table 5). People taking dasatinib and nilotinib spend the majority
of their lives in chronic phase on second-line treatment, whereas
those on interferon- spend most time in chronic phase on third-
ine treatment. For this reason, and because dasatinib and nilo-
inib are far more expensive per person per day than interferon-,
the expected per patient drug costs are far higher on dasatinib and
nilotinib compared with interferon-.
Compared with interferon-, nilotinib is expected to yield 1.2
more QALYs at £123,000 more per patient, yielding a very high
ICER of £104,700 QALY; dasatinib is expected to yield 2.2 more
QALYs at £185,000 more per patient, also yielding a very high ICER
of £82,600 QALY (Table 5); and dasatinib is expected to yield 1.1
more QALYs than nilotinib at £61,300 more per patient, also yield-
ing a high ICER of £58,000 QALY.
The predicted overall survival is lower for all treatments than
the empirical overall survival [3]. Therefore, in a sensitivity anal-
ysis, overall survival was calibrated to themostmature data avail-
able in an imatinib-intolerant population, and which was used for
the nilotinib data [22]. There is then no substantive change in the
cost-effectiveness estimates: the ICER for dasatinib versus inter-
feron- increases to £107,600 QALY, and for nilotinib versus inter-
eron- ICER is £132,900 QALY.
Full one-way deterministic sensitivity analyses are reported in
the online Appendix in Supplemental Materials at: 10.1016/j.j-
val.2011.07.006 and in Rogers et al. [3]. In summary, although the
ICERs for dasatinib and nilotinib versus interferon- were sensi-
ive to the method of estimating overall survival, the hazard ratio
or responders versus non-responders, and the PFS curve for da-
atinib/nilotinib, none of the parameter variations on their own
esulted in the ICER for dasatinib versus interferon- falling below
54,000 QALY or the ICER for nilotinib versus interferon- falling
below £48,000 QALY.
In the base-case analysis, the expected duration on dasatinib
treatment, at 10.8 years, is substantially greater than for nilotinib,
6.8 years. As for imatinib-resistant people, it appears that some
clinicians believe that the treatment durations should be approx-
imately equal. Nonetheless, even under these assumptions, both
drugs offer poor value for money: when we set the mean PFS for
nilotinib to equal that for dasatinib, the ICER for nilotinib versus
Table 5 – Base case results for imatinib-intolerant people.
Dasatinib Nilotinib
Life years mean, undiscounted (95% CI)
Chronic phase 2nd-line drugs 10.77 6.79
(5.51–15.52) (4.12–9.63)
Chronic phase 3rd-line treatment 1.94 3.87
(0.15–6.96) (0.93–9.40)
Accelerated phase* 0.8 0.8
Blast crisis* 1.09 1.09
Total, mean 14.6 12.55
(7.98–18.76) (7.65–15.93)
Total, median 12.47 9.67
(5.39–18.77) (5.12–14.36)
Total QALYs, mean, discounted 8.463 7.406
Costs, mean, discounted
2nd-line drug £244,926 £169,771
Other £38,515 £52,320
Total £283,441 £222,092
Cost/life year
Cost/QALY
Costs are given in pounds sterling (£).
95% CI, 95% confidence interval; QALY, quality-adjusted life years.
* Uncertainty not simulated.interferon- remains high at £142,000 QALY. Similarly, when weet the mean PFS for dasatinib to equal that for nilotinib, the ICER
or dasatinib versus interferon- remains high at £64,000 QALY.
In virtually all simulations of the probabilistic sensitivity anal-
ysis, both dasatinib and nilotinib incur greater lifetime costs and
benefits than interferon-. Interferon- is predicted to provide the
best value for money at all but the highest levels of willingness-
to-pay threshold (Fig. 2B).
Discussion
Given the structural assumptions in our base case, dasatinib is
highly unlikely to be cost-effective versus high-dose imatinib for
people resistant to normal-dose imatinib (ICER £91,500 QALY),
even when most key parameters are individually or simultane-
ously varied within plausible ranges. Given that dasatinib is
cheaper per patient per day (at the intended doses) and is pre-
dicted to give slightly greater life expectancy, one might expect
dasatinib to dominate high-dose imatinib. This is not the case for
two main reasons. First, we predict that dasatinib is typically
taken for far longer than high-dose imatinib (a mean of 6.5 vs. 2.7
years in the deterministic base case), thus incurring far greater
drug costs. Second, we estimate that the dose intensity for high-
dose imatinib is lower than for dasatinib (92% vs. 100%). As a re-
sult, estimated second-line drug costs for dasatinib are typically
about twice as high as for high-dose imatinib.
Although we predict that dasatinib is typically taken for far
longer than nilotinib (6.5 vs. 2.4 years) in our base case, life expec-
tancy is similar on both drugs [32]. This may appear counterintui-
tive. Furthermore, it appears that clinical opinion in the recent
NICE assessment for these drugs was that dasatinib and nilotinib
would be taken for approximately the same time. Therefore, the
sensitivity analysis whereby we set PFS for dasatinib equal to that
for nilotinib is important. Indeed, dasatinib is predicted to provide
good value for money only when we set PFS for dasatinib equal to
that for nilotinib or high-dose imatinib. Cost-effectiveness then
improves because dasatinib is predicted to be taken for far less
time, consequently incurring far lower drug cost.
Nilotinib dominates high-dose imatinib in the base case: nilo-
rferon- Dasatinib- interferon- Nilotinib- interferon-
2.04 8.73 4.75
.72–2.72) (3.34–13.40) (1.61–7.38)
6.82 4.88 2.95
.03–9.88) (8.85 to 0.71) (5.99 to 0.64)
0.8 0 0
1.09 0 0
10.75 3.85 1.8
.12–13.99) (0.84–6.60) (0.26–3.19)
7.75 4.72 1.92
.62–11.59) (0.67–9.25) (0.21–3.90)
6.229 2.235 1.177
£15,936 £228,990 £153,835
£98,818 £60,303 £46,498
£98,818 £184,623 £123,273
£47,951 £68,570
£82,619 £104,698Inte
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1066 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 5 7 – 1 0 6 7tient. Furthermore, nilotinib provides very good value for money
in all analyses except when PFS for nilotinib is set equal to that for
dasatinib, in which case the ICER is £128,000 QALY. Again, we
emphasize the importance of the sensitivity analysis.
The impact of an assumed relationship between overall sur-
vival and MCyR was tested in a sensitivity analysis in which the
surrogate approach was discarded and, instead, post-progression
survival was set equal for all treatments. This made very little
difference to the cost-effectiveness of nilotinib, but substantially
improved the cost-effectiveness of dasatinib (ICER fell to £43,200
QALY) because the far longer PFS seen with dasatinib was directly
reflected in longer overall survival for dasatinib.
For imatinib-intolerant people, the ICERs for nilotinib and da-
satinib versus interferon- are high in all analyses. This is because
the predicted QALY gains, although considerable, are insufficient
to outweigh the very high estimated costs of the new drugs. Both
nilotinib and dasatinib are far more expensive than interferon-
per person per day, and are predicted to be taken for far longer.
Kantarjian et al. [28] is the one relevant randomized study com-
arisonofdasatinib andhigh-dose imatinib.Nevertheless, this study
as not considered due to substantial patient crossover at an early
ollow-up time. Instead, estimates of clinical effectiveness are lim-
ted to a heterogeneous collection of observational evidence.
Effectiveness data are limited, but dasatinib and nilotinib appear
fficacious in terms of obtaining cytogenetic and hematological re-
ponses in both imatinib-resistant and -intolerant populations.
iven the limited evidence base, it ismore difficult to assess the extent
o which dasatinib and nilotinib induce greater frequencies and/or de-
rees of response, whichmay impact on long-termoutcomes.
The strengths of this assessment include the comprehensive, ex-
licit, and systematic literature searches used to locate evidence for
he reviewof clinical effectiveness and to inform the economicmod-
ling study, which is the information that is most certain (cytoge-
etic response rates) to predict long-term outcomes and the exten-
ive exploration of uncertainty. The model predicts the empirical
ata well: the fits to PFS distributions are good and the imatinib-
esistant model closely agrees with the empirical immature overall
urvival. The fit to the empirical imatinib-intolerant overall survival
s less convincing. However, the fit was very good using an alterna-
ive method of calibrating modeled overall survival.
The model should be viewed as an exploratory analysis of the
ost-effectiveness of dasatinib and nilotinib because it relies on
any assumptions. Some of the most substantive assumptions
re as follows. First, all clinical effectiveness data (e.g., MCyR and
FS) have necessarily been taken from single-arm trials, not from
andomized controlled trials, and progression is defined slightly
ifferently across trials. Second, a relationship is assumed be-
ween overall survival and MCyR, and
This relationship is the same for all treatments. Although this
appears reasonable for treatment with dasatinib and nilotinib,
there is no evidence to support this assumption;
The timing, duration, and depth of MCyR do not modify the
relationship;
The overall survival hazard ratio between responders and non-
responder in trials of first-line therapy with normal dose ima-
tinib remains constant over time and is transferable to the sec-
ond-line treatments;
The overall survival of imatinib-resistant patients taking high-
dose imatinib is used to calibrate the surrogate relationship
between MCyR and overall survival for all comparators in ima-
tinib-resistant and imatinib-intolerant CML.
Third,durationof treatment isestimated fromPFSwithadeduction
or premature discontinuations. Given that the PFS data is very imma-
ure, it is extrapolated many years into the future. Fourth, third-line
reatments are implicitly, not explicitly, modeled due to lack of data.
ifth, treatment-related adverse events incur no utility decrement and iocosts.Finally, theutilitiesforpeopletakingdasatinibandnilotinibare
ssumed equal to that for high-dose imatinib.
Given that the effectiveness data were taken from multinational
linical trialsandthecostdatawerebasedonpracticerelevanttotheUK
HS, the cost-effectiveness results are applicable to other countries
nly if thecostsare similar to those inother countries.Nonetheless, the
odeling framework can easily be adapted, with relevant cost data, to
nformonhealth policy decisions in other countries.
In their submission to NICE [23], BMS predicted that dasatinib
ould dominate high-dose imatinib,which is in stark contrast to our
rediction that dasatinib is not cost-effective. This is mainly attrib-
table to differences in the modeled experience of people taking
igh-dose imatinib. Inparticular, BMSpredicted farhigher treatment
osts on high-dose imatinib than we did and per patient discounted
osts of imatinib acquisition were £243,000 (BMS) versus £89,000 (pres-
nt study) for the following two reasons. First, and most importantly,
MS predicted average imatinib treatment duration of 8.8 years
hereas we predict 2.7 years. This difference arises because we use
ifferent clinical effectiveness data for imatinib. We use Jabbour et al.
12]whereasBMSusedKantarjianetal. [28].Weprefer Jabbouret al. [12]
because of the extensive treatment crossover in Kantarjian et al. [3].
Second, BMS assumed a dose intensity of 100% for high-dose imatinib,
whereasweassume92%, takenfromJabbouretal. [12]. If theBMSfigure
for treatment cost of high-dose imatinib is assumed, then our model
also predicts that dasatinib dominates high-dose imatinib.
Dasatinib has been assessed as good value for money versus
high-dose imatinib for people resistant to standard dose imatinib
in the Swedish healthcare system, according to a studywith finan-
cial support from BMS [10]. Based on a societal perspective, the
incremental cost is €6880 (in Euros) per QALY, and allowing for
direct costs only, €7207 per QALY (approximately £6000 [pound
sterling] per QALY). Given that this is a Swedish study, there are
many factors that differ from our analysis, including discount
rates, background mortality rates, unit prices, and resource use.
Nonetheless, the most important reason for the clear discrepancy
between the assessments of the cost-effectiveness of dasatinib
appears to be the fact that they predict that patients will take
high-dose imatinib for much longer than we do. This explains the
fact that they predict very similar per patient discounted drug
acquisition costs for dasatinib (€277,800) and imatinib (€278,200),
whereas we predict far higher drug acquisition costs for dasatinib
(£161,400) compared with imatinib (£88,900). This appears to be
the same reason that explains most of the discrepancy in cost-
effectiveness results between our model and that of BMS for the
NICE submission, namely that we use different clinical effective-
ness data for imatinib: we used Jabbour et al. [12] whereas BMS
used Kantarjian et al. [28]. We repeat that we favor Jabbour et al.
because of the extensive treatment crossover in Kantarjian et al.
[3].
In their submission to NICE [24], Novartis, the manufacturer of
nilotinib, agree with our prediction that nilotinib dominates high-
dose imatinib. Nevertheless, there is a major structural difference
between our models: Novartis estimates overall survival as PFS
plus time in accelerated phase plus time in blast crisis, whereas
we estimate overall survival according to the MCyR for each treat-
ment.We disagreewith theNovartis estimation of overall survival
because theremay be a substantial period duringwhich people are
in chronic phase, off second-line treatment [3].
Several randomized clinical trials of the interventions are un-
erway [3]. It is perhaps surprising that these are all open studies,
iven that the drugs are taken orally, and thus relatively easily
linded. A three-way, double blind, randomized clinical trial of
asatinib, nilotinib, and high-dose imatinib would be most useful
or informing a cost-effective model.
This study describes the cost-effectiveness analysis of nilotinib
or treatment of CML, and the cost-effectiveness analysis of dasat-
nib for treatment of CML conducted by a research team indepen-
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1067V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 5 7 – 1 0 6 7dent of financial support from the pharmaceutical industry. In
conclusion, we suggest that until longer follow up data for PFS and
overall survival are available, the cost-effectiveness of dasatinib
and nilotinib for imatinib-resistant people is highly uncertain. Our
findings that both nilotinib and dasatinib may not be cost-effec-
tive versus interferon- for people intolerant to imatinib are based
n plausible structural assumptions. We reiterate that our model
s reliant on many substantial assumptions. The most critical
hortcoming is that ourmodel is necessarily parameterized on the
asis of a heterogeneous collection of observational data, inwhich
he key outcomemeasures, MCyR and PFS, have been defined and
easured in different ways, at different times, in different popu-
ations.We recommend that the structure of ourmodel be re-used
hen higher quality data becomes available.
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